Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPB 111077

Next Previous
X
Search
Drug Profile

OPB 111077

Alternative Names: OPB-111077; OPC-317

Latest Information Update: 21 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical
  • Developer Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Signal transduction pathway inhibitors; STAT transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Acute myeloid leukaemia; Diffuse large B cell lymphoma
  • No development reported Liver cancer

Most Recent Events

  • 04 Mar 2024 Otsuka America Pharmaceutical completes a phase I trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03063944)
  • 09 Dec 2023 Efficacy and adverse events data from a phase I for Diffuse large B cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 16 Feb 2023 OPB 111077 is still in phase I for Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in Japan (PO) (NCT04049825)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top